The Daily Pulse

Health

UK health review flags over‑diagnosis of ADHD as prescriptions soar

Reported by Pooja Nair (Section Editor) · Google News - UK Health ·

Unconfirmed — Reported by one source so far

Reported by one source so far

Worth knowing
UK health review flags over‑diagnosis of ADHD as prescriptions soarRepresentative image · Wikimedia Commons

A new health review says ADHD symptoms alone should not trigger an automatic diagnosis. The review warns that relying only on symptom checklists can lead to too many people being labeled with the condition. At the same time, NHS officials have proposed a plan to limit the number of ADHD diagnoses, a move critics called rationing of healthcare. Data shows that prescriptions for ADHD medication have risen sixfold since the pandemic began. Private clinics that treat ADHD are now subject to stricter payment rules, adding pressure on non‑NHS providers. The combined concerns have sparked a wider debate about how ADHD should be assessed and treated in the UK.

ExplainerWhy this matters

What Happened

A health review highlighted that diagnosing ADHD solely on symptoms can lead to over‑diagnosis, while NHS plans to curb diagnoses face backlash and ADHD drug use has jumped sixfold since COVID‑19.

Why It Matters

Over‑diagnosis can mean children and adults receive unnecessary medication, exposing them to side effects and increasing healthcare costs. Limiting diagnoses without clear criteria may deny needed care to those who truly have ADHD. The surge in prescriptions suggests either more genuine cases or broader prescribing habits, both of which affect public health budgets and patient safety. Tougher payment rules for private providers could shift more patients to the NHS, straining already busy services.

What Happens Next

Policymakers are likely to refine diagnostic guidelines, possibly introducing stricter assessment protocols. Monitoring of prescription trends will continue, and private clinics may need to adapt to the new payment framework or focus on alternative therapies. Stakeholders will watch for any official statements clarifying how the NHS will balance limiting over‑diagnosis with ensuring access for genuine cases.

Read more at Google News - UK Health →